Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS 1
NCT05035095Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, sponsored by Novo Nordisk. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05035095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035095.